Subsequent Events	3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 16 - Subsequent Events Management has evaluated events that occurred subsequent to the end of the reporting period shown herein: As disclosed by the Company on press release from April 6, 2020 as well as in the Company’s last form 10-K, under PART I, ITEM 1: “Through the Joint Venture with Tokenize – It S.A., the parties commenced development of a development of an intelligent human vital signs’ device, which we currently refer to as qTerm. The platform is an expansion of the existing license agreement with GBT Tokenize Corp., which provided GBT Tokenize Corp. with an exclusive territory of California to develop certain of the Company’s technology. As the nature of the platform cannot be restricted only to California, the Company’s joint venture, GBT Tokenize Corp., will be compensated with an additional two hundred million shares of the Company to strengthen its funding, subject to board approval” – GBT Tokenize and the Company are in final negotiation for additional issuance of up to 500 million shares upon releasing of the first qTerm five working devices. The Company issued 9,236,453 shares of common stock in connection with the conversion of $150,000 of convertible notes.

Subsequent Events

3 Months Ended

Mar. 31, 2021

Note 16 - Subsequent Events

Management has evaluated events that occurred subsequent to the end of the reporting period shown herein:

As disclosed by the Company on press release from April 6, 2020 as well as in the Company’s last form 10-K, under PART I, ITEM 1: “Through the Joint Venture with Tokenize – It S.A., the parties commenced development of a development of an intelligent human vital signs’ device, which we currently refer to as qTerm. The platform is an expansion of the existing license agreement with GBT Tokenize Corp., which provided GBT Tokenize Corp. with an exclusive territory of California to develop certain of the Company’s technology. As the nature of the platform cannot be restricted only to California, the Company’s joint venture, GBT Tokenize Corp., will be compensated with an additional two hundred million shares of the Company to strengthen its funding, subject to board approval” – GBT Tokenize and the Company are in final negotiation for additional issuance of up to 500 million shares upon releasing of the first qTerm five working devices.

The Company issued 9,236,453 shares of common stock in connection with the conversion of $150,000 of convertible notes.